AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25294531 — intervention group
Group type: COMPARATOR
Intervention: GB left in situ (n = 45)
Number of subjects: 90
Study 23866812 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment based (ACT+FB) group
Number of subjects: 0
Study 23866812 — intervention group
Group type: COMPARATOR
Intervention: Feedback group (FB)
Number of subjects: 0
Study 23866812 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (FB and ACT+FB)
Number of subjects: 0
Study 21270329 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockade using propranolol
Number of subjects: 10
Study 21270329 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study 19500095 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-brief pulse bifrontal ECT at 1.5 times seizure threshold
Number of subjects: 64
Study 19500095 — intervention group
Group type: COMPARATOR
Intervention: Unilateral ECT at 6 times seizure threshold
Number of subjects: 64
Study 16860858 — intervention group
Group type: EXPERIMENTAL
Intervention: theory-based smoking cessation intervention
Number of subjects: 66
Study 16860858 — intervention group
Group type: COMPARATOR
Intervention: general health counseling (control)
Number of subjects: 66
Study 15327803 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to strong pain expressions (number of prior exposures varied across four groups)
Number of subjects: 80
Study 11132533 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha 6 MU tiw plus Ribavirin 14 mg/kg/day for 12 weeks
Number of subjects: 64
Study 11132533 — intervention group
Group type: COMPARATOR
Intervention: IFN alpha 6 MU tiw
Number of subjects: 64
Study 9309491 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 11
Study 9309491 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 11
Study 9309491 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fluoxetine and selegiline with physostigmine
Number of subjects: 11
Study 9309491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 8393474 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg)
Number of subjects: 101
Study 3565811 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium chloride (2.5 mg/kg in children; 4, 8, 12 mg/kg in dogs)
Number of subjects: 15
Study 3565811 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium gluconate (7.5 mg/kg in children; 14, 28, 42 mg/kg in dogs)
Number of subjects: 15
Study 31017496 — intervention group
Group type: COMPARATOR
Intervention: Intralesional verapamil alone (2.5mg/ml)
Number of subjects: 40
Study 31017496 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pulsed dye laser (PDL) and intralesional verapamil (2.5mg/ml)
Number of subjects: 40
Study 30355464 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care and radiotherapy (daily schedule: 55 Gy in 20 fractions over 4 weeks; weekly schedule: 36 Gy in six fractions over 6 weeks)
Number of subjects: 2061
Study 30355464 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 2061
Study 30355464 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care and radiotherapy
Number of subjects: 2061
Study 27251682 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI 50/25 µg, 100/25 µg or 200/25 µg, once daily
Number of subjects: 3255
Study 27251682 — intervention group
Group type: COMPARATOR
Intervention: VI 25 µg, once daily
Number of subjects: 3255
Study 24656240 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 1368
Study 24656240 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1368
Study 22856526 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened insemination method (4 hours)
Number of subjects: 0
Study 22856526 — intervention group
Group type: COMPARATOR
Intervention: Standard insemination method (16-18 hours)
Number of subjects: 0
Study 22856526 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue ICSI after failed fertilization with shortened insemination method
Number of subjects: 0
Study 20482251 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 25
Study 20482251 — intervention group
Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 25
Study 17850607 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus adjunctive CHX chip placement
Number of subjects: 36
Study 17850607 — intervention group
Group type: COMPARATOR
Intervention: SRP plus adjunctive systemic amoxicillin/metronidazole
Number of subjects: 36
Study 16288433 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic renal failure group
Number of subjects: 19
Study 16288433 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 19
Study 11902611 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-adhesive enamel coating applied to buccal surfaces of teeth in one quadrant
Number of subjects: 39
Study 11902611 — intervention group
Group type: COMPARATOR
Intervention: Untreated control quadrant
Number of subjects: 39
Study 11902611 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-adhesive enamel coating
Number of subjects: 39
Study 10203382 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic regimens for MAC (specific regimens not detailed)
Number of subjects: 0
Study 10203382 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline quantitative mycobacterial load
Number of subjects: 0
Study 10203382 — intervention group
Group type: EXPERIMENTAL
Intervention: Karnofsky score
Number of subjects: 0
Study 10203382 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous prophylaxis with rifabutin
Number of subjects: 0
Study 7802306 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg immediately and droperidol 0.16 mg with each PCA dose (Group 1)
Number of subjects: 80
Study 7802306 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg immediately (Group 2)
Number of subjects: 80
Study 7802306 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 0.16 mg with each PCA dose (Group 3)
Number of subjects: 80
Study 7802306 — intervention group
Group type: COMPARATOR
Intervention: No droperidol (Group 4)
Number of subjects: 80
Study 2148245 — intervention group
Group type: EXPERIMENTAL
Intervention: Large doses of MPA (Depo-Provera)
Number of subjects: 28
Study 7053117 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25%
Number of subjects: 105
Study 7053117 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125%
Number of subjects: 105
Study 7053117 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% after interruption of local anaesthetic infusion
Number of subjects: 105
Study 31931925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (10 mmHg CO2 pressure)
Number of subjects: 78
Study 31931925 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation group (12 mmHg CO2 pressure)
Number of subjects: 78
Study 31931925 — intervention group
Group type: COMPARATOR
Intervention: Negative control group (14 mmHg CO2 pressure)
Number of subjects: 78
Study 30206162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib combined with abiraterone
Number of subjects: 0
Study 30206162 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28125821 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC/5‐FU chemoradiotherapy
Number of subjects: 230
Study 28125821 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 230
Study 28125821 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC/5‐FU vs. no chemotherapy (necrosis present)
Number of subjects: 230
Study 28125821 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC/5‐FU vs. no chemotherapy (necrosis absent)
Number of subjects: 230
Study 28125821 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence vs. absence of necrosis
Number of subjects: 230
Study 26378938 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS 8
Number of subjects: 2884
Study 26378938 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS 13
Number of subjects: 2884
Study 26378938 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LNG-IUS 8 and LNG-IUS 13
Number of subjects: 2884
Study 23685099 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated intermittent bolus (5 mL every 30 min with 0.1 mL/hr basal rate)
Number of subjects: 45
Study 23685099 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion (10.1 mL/hr)
Number of subjects: 45
Study 23685099 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated intermittent bolus
Number of subjects: 45
Study 23685099 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion
Number of subjects: 45
Study 21509750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy plus standard care
Number of subjects: 0
Study 21509750 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 0
Study 19139445 — intervention group
Group type: EXPERIMENTAL
Intervention: Home fecal occult blood test (FOBT) kits offered during flu shot clinics
Number of subjects: 514
Study 19139445 — intervention group
Group type: COMPARATOR
Intervention: Control group (flu shots only)
Number of subjects: 514
Study 15865213 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a 180 microg
Number of subjects: 22
Study 15865213 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2b 1.0 microg/kg
Number of subjects: 22
Study 12870979 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer sealants (Fuji II LC) placed on primary molars
Number of subjects: 65
Study 10446101 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol (5 mg subcutaneously)
Number of subjects: 10
Study 10446101 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.6 mg then 0.25 mg/hour intravenously)
Number of subjects: 10
Study 10446101 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study 8709736 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA
Number of subjects: 10
Study 8709736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8709736 — intervention group
Group type: EXPERIMENTAL
Intervention: D-NMMA
Number of subjects: 10
Study 1810282 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Assessment Unit (GAU)
Number of subjects: 267
Study 1810282 — intervention group
Group type: COMPARATOR
Intervention: General Medical Units (GMUs)
Number of subjects: 267
Study 6818867 — intervention group
Group type: EXPERIMENTAL
Intervention: Special splint technique
Number of subjects: 41
Study 6818867 — intervention group
Group type: COMPARATOR
Intervention: Conventional splint system
Number of subjects: 41
Study 30910544 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome group
Number of subjects: 1508
Study 30910544 — intervention group
Group type: COMPARATOR
Intervention: Cumulative live birth rate
Number of subjects: 1508
Study 28849329 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone 24 mcg BID (CIC)
Number of subjects: 316
Study 28849329 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone 24 mcg BID (OIC)
Number of subjects: 316
Study 28849329 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone 8 mcg BID (IBS-C)
Number of subjects: 316
Study 28849329 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CIC)
Number of subjects: 316
Study 28849329 — intervention group
Group type: COMPARATOR
Intervention: Placebo (OIC)
Number of subjects: 316
Study 28849329 — intervention group
Group type: COMPARATOR
Intervention: Placebo (IBS-C)
Number of subjects: 316
Study 26259896 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) delivered by a trained sexual health professional
Number of subjects: 207
Study 26259896 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC) - standard alcohol leaflet
Number of subjects: 207
Study 25140033 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthpiece ventilation
Number of subjects: 50
Study 25140033 — intervention group
Group type: COMPARATOR
Intervention: Nasal mask ventilation
Number of subjects: 50
Study 21850553 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene mesh
Number of subjects: 35
Study 21850553 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene mesh
Number of subjects: 35
Study 19292961 — intervention group
Group type: EXPERIMENTAL
Intervention: Conductive education combined with Frenkel training
Number of subjects: 115
Study 19292961 — intervention group
Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 115
Study 17959973 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnia (ETco2 60 +/- 2 mm Hg)
Number of subjects: 180
Study 17959973 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocapnia (ETco2 27 +/- 2 mm Hg)
Number of subjects: 180
Study 17959973 — intervention group
Group type: COMPARATOR
Intervention: Normocapnia (ETco2 37 +/- 2 mm Hg)
Number of subjects: 180
Study 15793171 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (PC) program
Number of subjects: 198
Study 15793171 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 198
Study 11978650 — intervention group
Group type: COMPARATOR
Intervention: Systemic hyperinsulinemia
Number of subjects: 18
Study 11978650 — intervention group
Group type: COMPARATOR
Intervention: Locally administered insulin
Number of subjects: 18
Study 9579501 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (3 microg/ml) and fentanyl (1 ng/ml) with abrupt discontinuation (group 1A)
Number of subjects: 0
Study 9579501 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (3 microg/ml) and fentanyl (1 ng/ml) with abrupt discontinuation (group 2A)
Number of subjects: 0
Study 9579501 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (3 microg/ml) and fentanyl (1 ng/ml) with descending concentrations (group 1B)
Number of subjects: 0
Study 9579501 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (3 microg/ml) and fentanyl (1 ng/ml) with descending concentrations (group 2B)
Number of subjects: 0
Study 7657917 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home comprehensive geriatric assessment
Number of subjects: 81
Study 7657917 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician cooperation
Number of subjects: 81
Study 2482536 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b (Introna) 3 MU, 3 times weekly subcutaneously for 36 weeks
Number of subjects: 33
Study 2482536 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 33
Study 2482536 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b (Introna)
Number of subjects: 33
Study 320913 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% solution of metaproterenol, 10 whiffs (1.5 mg) q.i.d.
Number of subjects: 28
Study 320913 — intervention group
Group type: COMPARATOR
Intervention: 0.5% isoproterenol solution
Number of subjects: 28
Study 31289058 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cholecystectomy (within 6 days after discharge)
Number of subjects: 93
Study 31289058 — intervention group
Group type: COMPARATOR
Intervention: Delayed (interval) cholecystectomy (between 45 and 60 days after discharge)
Number of subjects: 93
Study 28566262 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20mg
Number of subjects: 0
Study 28566262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26024521 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux HD
Number of subjects: 127
Study 26024521 — intervention group
Group type: COMPARATOR
Intervention: Low-flux HD
Number of subjects: 127
Study 26024521 — intervention group
Group type: COMPARATOR
Intervention: Comparison between high-flux and low-flux HD
Number of subjects: 127
Study 23705968 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity training (HIT) intervention - 3 weekly exercise sessions over 7 weeks, consisting of 4 to 6 repeats of maximal sprint running with 30 s recovery
Number of subjects: 89
Study 23705968 — intervention group
Group type: COMPARATOR
Intervention: Control group - continued normal behavior
Number of subjects: 89
Study 21726354 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment for 3 days
Number of subjects: 130
Study 21726354 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment for 7 days
Number of subjects: 130
Study 19696132 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to suffering (experimental group)
Number of subjects: 89
Study 19696132 — intervention group
Group type: COMPARATOR
Intervention: Relaxing situations (control group)
Number of subjects: 89
Study 16428214 — intervention group
Group type: EXPERIMENTAL
Intervention: Swanson implants
Number of subjects: 53
Study 16428214 — intervention group
Group type: COMPARATOR
Intervention: Sutter implants
Number of subjects: 53
Study 14652361 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine 1.5 g/d
Number of subjects: 76
Study 14652361 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine 3 g/d
Number of subjects: 76
Study 14652361 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine 6 g/d
Number of subjects: 76
Study 11247402 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter ECG monitoring in patients with glucose metabolism disturbances
Number of subjects: 335
Study 11247402 — intervention group
Group type: COMPARATOR
Intervention: Holter ECG monitoring in patients without glucose metabolism disturbances
Number of subjects: 335
Study 11247402 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter ECG monitoring
Number of subjects: 335
Study 8651147 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment
Number of subjects: 0
Study 1633794 — intervention group
Group type: EXPERIMENTAL
Intervention: Force-paced lifting (4 lifts/min)
Number of subjects: 10
Study 1633794 — intervention group
Group type: COMPARATOR
Intervention: Self-paced lifting (random order)
Number of subjects: 10
Study 1633794 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pacing methods
Number of subjects: 10
Study 6392161 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix (ratio 3)
Number of subjects: 50
Study 6392161 — intervention group
Group type: COMPARATOR
Intervention: Renografin‐76 (ratio 1.5)
Number of subjects: 50
Study 31243928 — intervention group
Group type: EXPERIMENTAL
Intervention: PWC-positive group
Number of subjects: 110
Study 31243928 — intervention group
Group type: COMPARATOR
Intervention: PWC-negative group
Number of subjects: 110
Study 31243928 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 110
Study 30284674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileocolonic release peppermint oil (IC-PO) 182 mg
Number of subjects: 8
Study 30284674 — intervention group
Group type: COMPARATOR
Intervention: Small intestinal release peppermint oil (SI-PO) 182 mg
Number of subjects: 8
Study 26679155 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring cerebral oxygenation by near‐infrared spectroscopy (NIRS) combined with an evidence‐based treatment guideline
Number of subjects: 166
Study 26679155 — intervention group
Group type: COMPARATOR
Intervention: No NIRS data and treatment as usual
Number of subjects: 166
Study 24147767 — intervention group
Group type: EXPERIMENTAL
Intervention: Punctal plug use
Number of subjects: 39
Study 24147767 — intervention group
Group type: COMPARATOR
Intervention: Control (no punctal plug)
Number of subjects: 39
Study 22278623 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine + ARB
Number of subjects: 3293
Study 22278623 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine + β-blocker
Number of subjects: 3293
Study 22278623 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine + thiazide
Number of subjects: 3293
Study 19296834 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel treatment during pregnancy
Number of subjects: 387
Study 19296834 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment during pregnancy
Number of subjects: 387
Study 17970371 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in phonological awareness and letter-sound correspondence
Number of subjects: 109
Study 17970371 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 109
Study 15922201 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein procedure
Number of subjects: 334
Study 15922201 — intervention group
Group type: EXPERIMENTAL
Intervention: mesh plug repair
Number of subjects: 334
Study 15922201 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolene Hernia System
Number of subjects: 334
Study 15922201 — intervention group
Group type: EXPERIMENTAL
Intervention: neuropathic pain descriptions
Number of subjects: 334
Study 12530716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercessory prayer (nondirective method, no specific requests made)
Number of subjects: 8
Study 12530716 — intervention group
Group type: COMPARATOR
Intervention: Control group (not prayed for)
Number of subjects: 8
Study 11426515 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical antipsychotic agents
Number of subjects: 2378
Study 9219699 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFR:Fc 16 mg/m²
Number of subjects: 180
Study 9219699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 8435687 — intervention group
Group type: EXPERIMENTAL
Intervention: Dothiepin
Number of subjects: 219
Study 8435687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 2890459 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg with food
Number of subjects: 0
Study 2890459 — intervention group
Group type: COMPARATOR
Intervention: Nizatidine 150 mg with Gelusil
Number of subjects: 0
Study 2890459 — intervention group
Group type: COMPARATOR
Intervention: Nizatidine 150 mg with activated charcoal
Number of subjects: 0
Study 2890459 — intervention group
Group type: COMPARATOR
Intervention: Nizatidine 150 mg with propantheline
Number of subjects: 0
Study 29671676 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroretentive gabapentin
Number of subjects: 32
Study 29671676 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 32
Study 27464467 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tobacco cigarette smoking (smoked 2 cigarettes within 30-min)
Number of subjects: 30